What is the main business of Europejskie Centrum Sekwencjonowania Sp. z O.O. Modelowanie i Analiza Rna?

The main business activity of Europejskie Centrum Sekwencjonowania Sp. z O.O. Modelowanie i Analiza Rna focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on September 10, 2021.

Where is the headquarters located?

The headquarters is located at: ul. Święty Marcin 29, 61-806 Poznań.

What is the share capital?

The share capital of the company is PLN 6,000 (approx. $1,621).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2022 to December 31, 2022.

What was the revenue?

The company reported a revenue of $3,820 in 2022.

No, in 2022 the company was not profitable, reporting a net loss of $112,893. For comparison, in 2021 the loss was $19,993, meaning the company increased its loss by 551.3%.

Which cost dominates operating expenses?

The largest operating cost category falls under employee remuneration. This category amounted to $91,441 in 2022, representing 83% of all operating expenses.

Europejskie Centrum Sekwencjonowania Sp. z O.O. Modelowanie i Analiza Rnasp. k.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2021-09-10

Limited partner contribution

6,000.00 PLN

Registered address

ul. Święty Marcin 29/8, 61-806 Poznań, Poland

Financials

Revenue history

Filing timeliness

No financial statement for 2023 – the filing deadline has passed. 1 of 2 financial statements was filed late (for 2022, 2 days late).

2023not filed
202217/07/2023
202129/06/2022

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2022.

Industry · Research and experimental development on biotechnology283 / 386

Top 73%

Division · Scientific research and development1,537 / 1,953

Top 79%

Sector · Professional, scientific and technical activities33,774 / 39,213

Top 86%

Voivodeship · Wielkopolskie42,983 / 49,540

Top 87%

Country · Poland428,184 / 495,860

Top 86%

Results vs industry

Revenue

This companyUSD 3.82kMedianUSD 55.24kAverageUSD 2.70m

Net profit

This companyUSD -112.89kMedianUSD -1.27kAverageUSD -92.18k

Operating costs

This companyUSD 109.70kMedianUSD 65.85kAverageUSD 2.66m

Assets

This companyUSD 102.21kMedianUSD 133.19kAverageUSD 3.03m

Industry

Partners

Partners	Partner role
Europejskie Centrum Sekwencjonowania sp. z o.o.	General partner
Paulina Grudzińskaage 41	General partner

Manner of representation

Each general partner represents the company independently.

Beneficial owners

Person	Rights

Bank accounts

Was a VAT taxpayer from 2021-12-10 to 2024-10-14.

Reason for removal: Art. 96 ust. 9a pkt 2 (VAT returns not filed for 3 consecutive months or a quarter)

Debt

1 closed proceeding recorded in KRZ history.

Registration date	Proceeding type	Status
Mar 6, 2026	Discontinued enforcement proceedings	Closed

MSiG notices

Publication date	Event
Jul 5, 2024	Dissolution without liquidation opened

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
GenxoneS.A.	$665,361.35	genxone.eu
Polbiotech Laboratoriumsp. z o.o.	$645,943.81	polbiotech.pl
Relvosp. z o.o.	$120,693.26	relvo.pl
Microblicsp. z o.o.	$122,383.50	microblic.pl
Xenstatssp. z o.o.	$66,774.27	xenstats.com
Poltisssp. z o.o.	$3,843.72	poltiss.com
Omnisepticasp. z o.o.	$3,475.29	omniseptica.com
Fungotechsp. z o.o.	$187.68	fungo.tech
Dystrogen TherapeuticsS.A.	–	dystrogen.com
MIMO BiotechP.S.A.	–	mimobiotech.com